Latest news with #OMA
Business Insider
20 hours ago
- Business
- Business Insider
OMA downgraded to Market Perform from Outperform at Itau BBA
Itau BBA downgraded OMA (OMAB) to Market Perform from Outperform with a MXN 236 price target The firm cites valuation following the stock's 31% run and limited earnings momentum for the downgrade. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Observer
4 days ago
- Automotive
- Observer
Al Rawahi holds second place at the Jordan Rally
JORDAN: Oman Rally Team star Abdullah al Rawahi delivered one of the best performances of his career on the first day of the Jordan Rally. After six demanding gravel stages in the Dead Sea and Jordan Valley areas, the Autotek Škoda Fabia driver trailed the 19-time FIA Middle East champion Nasser Saleh al Attiyah by just 13.5 seconds. This was despite a slow puncture towards the end of the last stage. Al Rawahi and his Jordanian co-driver Ata al Hmoud are bidding to win the FIA Middle East Rally Championship (MERC) title for a second time, as well as trying to win the event in Jordan once again. The performance today also netted them the win in the opening round of the Jordan National Championship. At the end of a dramatic day, where Al Attiyah and Al Rawahi were the class of the entire field. Al Rawahi said: 'I think this rally overall is very tough and it is not easy to challenge Nasser over these stages. He has won it 16 times. Being just behind him and able to take some time, I am very happy. Tomorrow, is another day. We must also remember that I have an older car. I think we should be happy with the result today. I think we are on the limit. I don't think we can push any harder and we don't want mistakes.' Al Rawahi was in scintillating form on the opening loop of three stages where he was more than a match for the road-sweeping Al Attiyah. The duo was separated by just 0.6 seconds on the 32 km opening speed test at Tal Hilali and then by a mere one-tenth of a second on stage two. But Al Rawahi was faster than his Qatari rival on the third stage of the loop at the historic Baptism Site and edged into a slender 0.8-second lead at the midday point. Ata al Hmoud and Abdullah al Rawahi (R) Al Rawahi said: 'It was a good day for us so far. The stages are quite tough and very tricky. We had a few moments but the times are good overall and we are leading after the first loop. I think we just need to keep focused and try to do our best. We need to be very consistent with our performance. You have no other choice but to go flat out. This afternoon, the same.' Saturday's remaining three stages are repeated twice with action getting underway with a run though the Panorama stage of 17.12 km. The first passes through the Suwayma and Wadi Nar specials complete the morning's loop. The three timed tests are repeated in the afternoon before the post-event press conference and traditional ceremonial finish at the Dead Sea. 2025 Jordan Rally — positions after SS6 (unofficial): 1. Nasser Saleh al Attiyah (QAT)/Candido Carrera (ESP) Škoda Fabia RS Rally 2 1 hr 16 min 10.7 sec 2. Abdullah al Rawahi (OMA)/Ata al Hmoud (JOR) Škoda Fabia R5 Rally 2 1 hr 16 min 24.2 sec 3. Abdulaziz al Kuwari (QAT)/Lorcan Moore (IRL) Citroën C3 Rally 2 1 hr 18 min 29.6 sec 4. Rakan al Rashed (KSA)/Hugo Magalhães (POR) Toyota GR Yaris Rally 2 1 hr 23 min 46.9 sec 5. Bassel Abu Hamdan (KSA)/Firas Elias (LBN) Škoda Fabia R5 Rally 2 1 hr 27 min 24.3 sec 6. Abdullah al Zubair (OMA)/Taha al Zadjali (OMA) Subaru Impreza N14 1 hr 27 min 43.4 sec 7. Nasser Khalifa al Attiyah (QAT)/Ziad Chehab (LBN) Ford Fiesta Mk II Rally 2 1 hr 28 min 01.5 sec 8. Shadi Shaban (JOR)/Samer Issa (JOR) Mitsubishi Lancer Evo IX (NAT) 1 hr 28 min 47,6 sec 9. Zakariya al Aamri (OMA)/Mohammed al Mazroui (OMA) Subaru Impreza N14 1 hr 31 min 25.9 sec 10. Ihab al Shurafa (JOR)/Ahmad Jankhout (JOR) Škoda Fabia Evo Rally 2 1 hr 32 min 51.6 sec 11. Rashid al Muhannadi (QAT)/Gary McElhinney (IRL) Peugeot 208 Rally 4 1 hr 32 min 57.0 sec 12. Sheikh Bader al Fayez (JOR)/Vili Oslaj (SLO) Škoda Fabia Rally 2 1 hr 33 min 42.4 sec 13. Shadi El Fakih (LBN)/Joseph Kmeid (LBN) Mitsubishi Lancer Evo X 1 hr 45 min 00.1 sec 14. Jassim al Muqahwi (KUW)/Suleiman al Helal (KUW) Mitsubishi Lancer Evo X 1 hr 46 min 32.3 sec
Observer
26-05-2025
- Automotive
- Observer
Jordan Rally attracts 21 starters this weekend
AMMAN, Jordan: Twenty-one crews will tackle the opening two rounds of this year's Jordan National Championship that are being held In conjunction with days one and two of this weekend's Jordan Rally, round four of the FIA Middle East Rally Championship (MERC). Nine crews are eligible to score points in both the FIA event and the two national rallies with an additional 12 teams running at the rear of the field and solely targeting local championship points. Each of the two national events on Friday and Saturday will run over six gravel special stages in the Dead Sea and Jordan Valley areas. Oman's Abdullah al Rawahi is a former winner of the FIA event and is the top seed for national success, where he faces Rally2 opposition from Shaikh Bader al Fayez and Ihab al Shorafa, all three of whom drive Škoda Fabias this weekend. Defending MERC champion Abdulaziz al Kuwari and his co-driver Marshall Clarke won the Jordan National Championship last season, but the Qatari is not scoring points this year. He is solely targeting the FIA event in a Citroën C3. Al Fayez was the runner-up in the national series in 2024 with Shadi Shaban finishing third. Shaban also topped the standings in the NR4 group with Group MT success falling to Salama al Ghammaz and Hashim al Kalbouneh winning Group T in his Black Iris. Hashim al Kalbouneh Shaker Jweihan is the defending regional MERC2 champion and he will be aiming for national podium success in a Mitsubishi Lancer Evolution X. Palestine's Hamada Uda also drives the latest version of the Mitsubishi and there are a fleet of Evo IXs for Shaban, Mohammed al Shorafa, Lebanon's Joanna Hassoun, Issa Abu Jamous and Fadi Dhashan. Fayez al Ghammaz and Faisal al Ghammaz wheel out older versions of the all-conquering Mitsubishi. Oman's Zakariya al Aamri is the current leader of the FIA MERC2 category and is also chasing Jordan National Championship points in his Subaru. Bader al Helalat, Amjad al Sheikh and Asem Aref drive older versions of the renowned Impreza rally car. Al Kalbouneh returns to action with his Black Iris and last year's FIA Middle East Baja Cup's Stock champion Majed al Thunayyan is making the trip from Saudi Arabia to tackle the event in a Nissan Patrol. The Jordanian trio of Yahia Sobar (Toyota FJ), Karim Badawi (Suzuki) and Farah Zakaria (Can-Am) round off the impressive national field. This year's Jordan Rally is supported by Zain Jordan, Guarantee Travel Group, Hala and Bliss FM, Markazia and Toyota Gazoo Racing Jordan. Shaikh Bader al Fayez 2025 Jordan National Rally – Entry List: 3. Abdullah al Rawahi (OMA)/Ata Al-Hmoud (JOR) Škoda Fabia R5 Rally 2 6. Sheikh Bader al Fayez (JOR)/Vili Oslaj (SLO) Škoda Fabia Rally 2 7. Ihab al Shurafa (JOR)/Ahmad Jankhout (JOR) Škoda Fabia Evo Rally 2 10. Shaker Jweihan (JOR)/Aisvydas Paliukenas (LTU) Mitsubishi Lancer Evo X 13. Zakariya al Aamri (OMA)/Mohammed al Mazroui (OMA) Subaru Impreza N14 15. Hamada Uda (PAL)/Mustafa Juma (JOR) Mitsubishi Lancer Evo X 20. Shadi Shaban (JOR)/Samer Issa (JOR) Mitsubishi Lancer Evo IX 21. Mohammed al Shorafa (JOR)/Yazan Juma (JOR) Mitsubishi Lancer Evo IX 22. Joanna Hassoun (LBN)/Sami Fleifel (JOR) Mitsubishi Lancer Evo IX 30. Issa Abu Jamous (JOR)/Saqer Abu Jamous (JOR) Mitsubishi Lancer Evo IX 31. Fadi Dahshan (JOR)/Raed Dahshan (JOR) Mitsubishi Lancer Evo IX 32. Fayez al Ghammaz (JOR)/Salameh al Ghammaz (JOR) Mitsubishi Lancer Evo VI 33. Bader al Helalat (JOR)/Amer Mousa (JOR) Subaru Impreza 34. Faisal al Ghammaz (JOR)/Mamdouh Juma (JOR) Mitsubishi Lancer Evo VIII 35. Amjad al Shaikh (JOR)/Abdullah Ibdah (JOR) Subaru Impreza 36. Asem Aref (JOR)/Musa Djiyerian (JOR) Subaru Impreza 37. Hashim al Kalbouneh (JOR)/Dergham Rustom (JOR) Black Iris Prototype 38. Majid al Thunayyan (KSA)/Fahed al Sufyani (KSA) Nissan Patrol Y61 39. Yahia Sobar (JOR)/Hamzeh Qabshoura (JOR) Toyota FJ Cruiser 40. Karim Badawi (JOR)/Walid Shabsogh (JOR) Suzuki Samarai 41. Farah Zakaria (JOR)/Bayan Zakaria (JOR) Can-Am Maverick
The Hill
16-05-2025
- Health
- The Hill
Are weight loss drugs safe? Learn some of the side effects
Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects caused by some of the more well-known medications like Ozempic and Mounjaro. According to the Obesity Medicine Association (OMA), researchers are continually analyzing the pros and cons of these drugs. Here are some side effects of the eight FDA-approved weight loss drugs: Ozempic and Wegovy are the brand names of a drug known as semaglutide, a medication that, according to Harvard Health, has been prescribed for about two decades to treat Type 2 diabetes. Ozempic has become controversial over the past few years as overweight and obese patients have sought it out for weight loss, creating a shortage of the drug for those using it to control their diabetes. Wegovy is the brand name for a form of semaglutide that has since been approved for weight loss. Semaglutide, which mimics a natural hormone called GLP-1, helps regulate blood sugar while slowing down the emptying of the stomach and signaling satiety or fullness to the brain. The OMA reports that the most common complaint among patients using semaglutide is gastrointestinal issues like nausea. Other side effects include fatigue, dizziness, headache, bloating, belching and heartburn. An American Medical Association study has also found that GLP-1 agonists are associated with an increased risk of pancreatitis, bowel obstruction, and gastroparesis. While headlines have warned about an increase in suicidal ideation with semaglutide, a January 2024 study in Nature Medicine suggested 'a 49% to 73% lower risk of first-time or recurring suicidal ideations' compared with other obesity medications. Mounjaro and Zepbound are drugs known as tirzepatide. Mounjaro was approved in 2017 to treat Type 2 diabetes, while Zepbound was approved in more recent years to treat obesity. Like semaglutide, tirzepatide is a GLP-1 agonist that increases a person's feeling of fullness and helps them maintain a weight loss diet. It causes common mild symptoms like nausea, constipation, diarrhea and bloating, but the OMA reports more serious side effects like kidney problems up to and including kidney failure, gallbladder symptoms, pancreatitis and hypoglycemia. Manufacturer Eli Lilly warns, however, that Tirzepatide may cause thyroid tumors or thyroid cancer. Patients should monitor themselves for symptoms like neck swelling, hoarseness, problems swallowing and shortness of breath. Contrave is the brand name for a medication that combines two drugs, bupropion and naltrexone. Bupropion, which is marketed under the brand name Wellbutrin, is an antidepressant that is also known to reduce a person's appetite. Naltrexone, commonly sold under the brand names Revia and Vivitrol, is a medication used to treat drug and alcohol addiction. According to naltrexone works by blocking the euphoric, intoxicated feeling of alcohol and opioids. It also helps reduce the cravings for the substances. The OMA reports that patients should not be prescribed Contrave if they suffer from a seizure disorder or if they take opioids for chronic pain. The most common side effects of the drug are nausea, vomiting, constipation, diarrhea, headache, dizziness, dry mouth and insomnia. Saxenda is a medication containing liraglutide, a drug that mimics a person's natural hormones affecting hunger, digestion and feelings of fullness. It was approved by the FDA in 2017 to treat obesity in people 12 and older. The most common side effects of liraglutide are nausea, vomiting, constipation, diarrhea, headache, fatigue, dyspepsia, dizziness and abdominal pain. It can also cause increased heart rate, increased lipase, which is a pancreatic enzyme, and decreased kidney function. Qsymia is a medication that combines the drugs phentermine and topiramate. According to the OMA, phentermine has been around since 1959, making it the oldest and most widely used weight loss medication. The drug, which works in the brain as an appetite suppressant, is a stimulant similar to amphetamines and can be abused. It should not be used by patients who have suffered a stroke or who have heart disease, glaucoma or hyperthyroidism. The side effects of phentermine can be serious, including fast or irregular heart rate, headache, overstimulation, high blood pressure and tremors. It can also interact with several other drugs, including MAO inhibitors, alcohol, adrenergic neuron blockers and some anesthetic agents. When phentermine is combined with topiramate, an anticonvulsant, its effect on hunger is magnified. The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and dry mouth. Topiramate also carries a risk of birth defects, so it should not be taken during pregnancy. Qsymia was approved in 2021 for chronic weight management in adults. It was approved the following year for pediatric patients ages 12 and older who have a body mass index in the 95th percentile or greater. Imcivree, which is the brand name for setmelanotide, is approved by the FDA to treat patients suffering from severe obesity caused by rare genetic disorders. According to the National Institute of Health, setmelanotide is used to treat POMC, PCSK1 and LEPR deficiencies, which all lead to early-onset obesity. According to manufacturer Rhythm Pharmaceuticals, it is also used to treat Bardet-Biedl syndrome in patients aged 2 and older. Setmelanotide works by targeting the impaired MC4R pathway in the brain, which allows it to deliver messages to the brain that the body is satisfied and doesn't need more food. The National Institutes of Health (NIH) reports that it helps restore appetite control, reduces the patient's food intake and helps to control weight gain. It does not treat the underlying genetic defects that lead to obesity. The most common side effects of Imcivree are reactions at the injection site, hyperpigmentation, nausea, vomiting, headache, diarrhea, stomach pain and depression. More serious side effects include sexual dysfunction, depression, suicidal thoughts or actions and toxicity caused by benzyl alcohol, which is a preservative in Imcivree. Like most medications, it can also cause serious allergic reactions that include swelling of the face, lips, tongue or throat, breathing or swallowing issues, severe rash, itching, dizziness and rapid heartbeat. Anyone who experiences an allergic reaction should seek immediate medical attention. NewsNation's Taylor Delandro contributed to this report.
Yahoo
15-05-2025
- Health
- Yahoo
Are weight loss drugs safe? Learn some of the side effects
(NewsNation) — Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects caused by some of the more well-known medications like Ozempic and Mounjaro. According to the Obesity Medicine Association, researchers are continually analyzing the side effects of these drugs. Here are some side effects of the eight FDA-approved weight loss drugs: Ozempic and Wegovy are the brand names of a drug known as semaglutide, a medication that, according to Harvard Health, has been prescribed for about two decades to treat Type 2 diabetes. Ozempic has become controversial over the past few years as overweight and obese patients have sought it out for weight loss, creating a shortage of the drug for those using it to control their diabetes. Wegovy is the brand name for a form of semaglutide that has since been approved for weight loss. Semaglutide, which mimics a natural hormone called GLP-1, helps regulate blood sugar while slowing down the emptying of the stomach and signaling satiety or fullness to the brain. What's the difference between Ozempic, Wegovy, other weight loss drugs? The OMA reports that the most common complaint among patients using semaglutide is gastrointestinal issues like nausea. Other side effects include fatigue, dizziness, headache, bloating, belching and heartburn. An American Medical Association study has also found that GLP-1 agonists are associated with an increased risk of pancreatitis, bowel obstruction, and gastroparesis. While headlines have warned about an increase in suicidal ideation with semaglutide, a January 2024 study in Nature Medicine suggested 'a 49% to 73% lower risk of first-time or recurring suicidal ideations' compared with other obesity medications. Mounjaro and Zepbound are drugs known as tirzepatide. Mounjaro was approved in 2017 to treat Type 2 diabetes, while Zepbound was approved in more recent years to treat obesity. Like semaglutide, tirzepatide is a GLP-1 agonist that increases a person's feeling of fullness and helps them maintain a weight loss diet. Some drugs more effective for weight loss than Ozempic: Study It causes common mild symptoms like nausea, constipation, diarrhea and bloating, but the OMA reports more serious side effects like kidney problems up to and including kidney failure, gallbladder symptoms, pancreatitis and hypoglycemia. Manufacturer Eli Lilly warns, however, that Tirzepatide may cause thyroid tumors or thyroid cancer. Patients should monitor themselves for symptoms like neck swelling, hoarseness, problems swallowing and shortness of breath. Contrave is the brand name for a medication that combines two drugs, bupropion and naltrexone. Bupropion, which is marketed under the brand name Wellbutrin, is an antidepressant that is also known to reduce a person's appetite. Naltrexone, commonly sold under the brand names Revia and Vivitrol, is a medication used to treat drug and alcohol addiction. According to naltrexone works by blocking the euphoric, intoxicated feeling of alcohol and opioids. It also helps reduce the cravings for the substances. FAQ: How do Ozempic, weight-loss drugs work? The OMA reports that patients should not be prescribed Contrave if they suffer from a seizure disorder or if they take opioids for chronic pain. The most common side effects of the drug are nausea, vomiting, constipation, diarrhea, headache, dizziness, dry mouth and insomnia. Saxenda is a medication containing liraglutide, a drug that mimics a person's natural hormones affecting hunger, digestion and feelings of fullness. It was approved by the FDA in 2017 to treat obesity in people 12 and older. The most common side effects of liraglutide are nausea, vomiting, constipation, diarrhea, headache, fatigue, dyspepsia, dizziness and abdominal pain. It can also cause increased heart rate, increased lipase, which is a pancreatic enzyme, and decreased kidney function. Qsymia is a medication that combines the drugs phentermine and topiramate. According to the OMA, phentermine has been around since 1959, making it the oldest and most widely used weight loss medication. The drug, which works in the brain as an appetite suppressant, is a stimulant similar to amphetamines and can be abused. It should not be used by patients who have suffered a stroke or who have heart disease, glaucoma or hyperthyroidism. The side effects of phentermine can be serious, including fast or irregular heart rate, headache, overstimulation, high blood pressure and tremors. It can also interact with several other drugs, including MAO inhibitors, alcohol, adrenergic neuron blockers and some anesthetic agents. How many people use injectable weight loss drugs? When phentermine is combined with topiramate, an anticonvulsant, its effect on hunger is magnified. The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and dry mouth. Topiramate also carries a risk of birth defects, so it should not be taken during pregnancy. Qsymia was approved in 2021 for chronic weight management in adults. It was approved the following year for pediatric patients ages 12 and older who have a body mass index in the 95th percentile or greater. Imcivree, which is the brand name for setmelanotide, is approved by the FDA to treat patients suffering from severe obesity caused by rare genetic disorders. According to the National Institute of Health, setmelanotide is used to treat POMC, PCSK1 and LEPR deficiencies, which all lead to early-onset obesity. According to manufacturer Rhythm Pharmaceuticals, it is also used to treat Bardet-Biedl syndrome in patients aged 2 and older. Setmelanotide works by targeting the impaired MC4R pathway in the brain, which allows it to deliver messages to the brain that the body is satisfied and doesn't need more food. The National Institute of Health reports that it helps restore appetite control, reduces the patient's food intake and helps to control weight gain. About half of Americans approve of using weight-loss drugs: Poll It does not treat the underlying genetic defects that lead to obesity. The most common side effects of Imcivree are reactions at the injection site, hyperpigmentation, nausea, vomiting, headache, diarrhea, stomach pain and depression. More serious side effects include sexual dysfunction, depression, suicidal thoughts or actions and toxicity caused by benzyl alcohol, which is a preservative in Imcivree. Like most medications, it can also cause serious allergic reactions that include swelling of the face, lips, tongue or throat, breathing or swallowing issues, severe rash, itching, dizziness and rapid heartbeat. Anyone who experiences an allergic reaction should seek immediate medical attention. NewsNation's Taylor Delandro contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
